Summary:
A Double-Blind, Placebo-Controlled Study of Brexpiprazole plus Ketamine in Treatment-Resistant Depression (TRD)
Qualified Participants Must:
Male or female, 18 to 65 years of age
Qualified Participants May Receive:
Compensation for time and travel